이뮤닉스(IMUX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $10.72 (+3.57%), 시가총액 $0.16B, 52주 최저~최고 $0.51 ~ $12.95.
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with d
이뮤닉스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
이뮤닉스의 현재 주가는 $10.72 (+3.57%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
이뮤닉스의 시가총액은 약 $0.16B입니다.
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. I